Brief: Compugen's COM701 (Anti-PVRIG) Mediates Anti-Tumor Activity In Patients Typically Not Responding To Immunotherapy
06/11/2023 12:17
Nov 6 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN'S COM701 (ANTI-PVRIG) MEDIATES ANTI-TUMOR
ACTIVITY IN
PATIENTS TYPICALLY NOT RESPONDING TO IMMUNOTHERAPY
* COMPUGEN LTD - COM701 DUAL AND TRIPLE COMBINATIONS
MEDIATED
CLINICAL BENEFIT IN PLATINUM RESISTANT OVARIAN CANCER PATIENTS
Source text for Eikon: ID:nPn6MfLSKa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025